Pharming Group (PHAR) Competitors $14.87 +0.51 (+3.55%) Closing price 03:59 PM EasternExtended Trading$14.88 +0.01 (+0.07%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHAR vs. MIRM, MLTX, PTGX, APLS, MENS, MTSR, SRRK, KYMR, AMRX, and XENEShould you be buying Pharming Group stock or one of its competitors? The main competitors of Pharming Group include Mirum Pharmaceuticals (MIRM), MoonLake Immunotherapeutics (MLTX), Protagonist Therapeutics (PTGX), Apellis Pharmaceuticals (APLS), Jyong Biotech (MENS), Metsera (MTSR), Scholar Rock (SRRK), Kymera Therapeutics (KYMR), AMNEAL PHARMACEUTICALS (AMRX), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical products" industry. Pharming Group vs. Its Competitors Mirum Pharmaceuticals MoonLake Immunotherapeutics Protagonist Therapeutics Apellis Pharmaceuticals Jyong Biotech Metsera Scholar Rock Kymera Therapeutics AMNEAL PHARMACEUTICALS Xenon Pharmaceuticals Pharming Group (NASDAQ:PHAR) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings. Is PHAR or MIRM more profitable? Pharming Group has a net margin of -2.19% compared to Mirum Pharmaceuticals' net margin of -13.65%. Pharming Group's return on equity of -3.31% beat Mirum Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Pharming Group-2.19% -3.31% -1.78% Mirum Pharmaceuticals -13.65%-24.76%-8.50% Which has more volatility & risk, PHAR or MIRM? Pharming Group has a beta of 0.05, suggesting that its share price is 95% less volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Do insiders and institutionals hold more shares of PHAR or MIRM? 0.0% of Pharming Group shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by company insiders. Comparatively, 14.4% of Mirum Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has higher earnings and valuation, PHAR or MIRM? Pharming Group has higher earnings, but lower revenue than Mirum Pharmaceuticals. Pharming Group is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPharming Group$297.20M3.43-$11.84M-$0.13-114.38Mirum Pharmaceuticals$336.89M11.06-$87.94M-$1.21-61.31 Does the media refer more to PHAR or MIRM? In the previous week, Mirum Pharmaceuticals had 7 more articles in the media than Pharming Group. MarketBeat recorded 12 mentions for Mirum Pharmaceuticals and 5 mentions for Pharming Group. Mirum Pharmaceuticals' average media sentiment score of 1.35 beat Pharming Group's score of 0.68 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharming Group 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 12 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate PHAR or MIRM? Pharming Group presently has a consensus price target of $30.00, suggesting a potential upside of 101.75%. Mirum Pharmaceuticals has a consensus price target of $74.13, suggesting a potential downside of 0.07%. Given Pharming Group's higher possible upside, equities analysts plainly believe Pharming Group is more favorable than Mirum Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pharming Group 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Mirum Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 SummaryMirum Pharmaceuticals beats Pharming Group on 10 of the 17 factors compared between the two stocks. Get Pharming Group News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHAR vs. The Competition Export to ExcelMetricPharming GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$983.87M$3.13B$5.76B$9.85BDividend YieldN/A2.28%6.71%4.51%P/E Ratio-114.387.5859.1122.53Price / Sales3.43458.96547.00119.09Price / Cash193.7244.5237.0558.92Price / Book4.589.9310.916.06Net Income-$11.84M-$53.38M$3.29B$266.28M7 Day Performance1.92%0.05%0.01%-0.76%1 Month Performance21.39%7.08%7.06%3.83%1 Year Performance99.33%11.92%50.09%24.39% Pharming Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHARPharming Group2.9378 of 5 stars$14.87+3.6%$30.00+101.7%+87.5%$983.87M$297.20M-114.38280News CoveragePositive NewsShort Interest ↓Gap DownMIRMMirum Pharmaceuticals3.2865 of 5 stars$71.81+0.4%$74.13+3.2%+80.6%$3.59B$336.89M-59.35140Positive NewsMLTXMoonLake Immunotherapeutics1.5828 of 5 stars$54.63-2.3%$74.43+36.2%+28.5%$3.59BN/A-19.652News CoveragePositive NewsAnalyst RevisionPTGXProtagonist Therapeutics1.7525 of 5 stars$56.88-1.0%$67.20+18.1%+40.3%$3.58B$434.43M81.26120News CoveragePositive NewsAPLSApellis Pharmaceuticals4.319 of 5 stars$27.52-1.6%$34.12+24.0%-28.4%$3.53B$781.37M-15.12770News CoveragePositive NewsMENSJyong BiotechN/A$47.00+2.2%N/AN/A$3.50BN/A0.0031News CoverageGap DownMTSRMetseraN/A$32.59-1.4%$55.00+68.8%N/A$3.47BN/A0.0081News CoverageAnalyst ForecastSRRKScholar Rock4.62 of 5 stars$33.33-6.1%$45.75+37.3%+277.8%$3.41B$33.19M-11.45140News CoveragePositive NewsKYMRKymera Therapeutics3.4778 of 5 stars$41.82-5.2%$58.76+40.5%-6.5%$3.15B$44.71M-12.05170News CoveragePositive NewsAMRXAMNEAL PHARMACEUTICALS3.0532 of 5 stars$9.28-3.2%$11.60+25.0%+12.4%$3.01B$2.79B928.938,100Positive NewsXENEXenon Pharmaceuticals2.6985 of 5 stars$38.14-1.8%$53.20+39.5%-3.3%$2.99B$9.43M-10.74210News CoveragePositive NewsAnalyst ForecastOptions Volume Related Companies and Tools Related Companies MIRM Competitors MLTX Competitors PTGX Competitors APLS Competitors MENS Competitors MTSR Competitors SRRK Competitors KYMR Competitors AMRX Competitors XENE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHAR) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredTrump’s national nightmare is hereWashington just added $1 trillion to the national debt in less than two months — an astonishing pace of spendi...Porter & Company | SponsoredWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...Chaikin Analytics | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Shadow Group” in Washington, DC Could Crash MarketNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharming Group N.V. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharming Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
